Learn about the global oral biologics & biosimilar drugs market through The Business Research Company, which provides information on oral biologics & biosimilar drugs market size, oral biologics & biosimilar drugs market drivers and restraints, oral biologics & biosimilar drugs market players, the COVID-19 impact on the oral biologics & biosimilar drugs market, and more.

The global oral biologics & biosimilar drugs market size is expected to grow from $4.06 billion in 2021 to $4.91 billion in 2022 at a compound annual growth rate (CAGR) of 21%. The growth in the market is mainly due to the companies resuming their operations and adapting to the new normal while recovering from the COVID-19 impact, which had earlier led to restrictive containment measures involving social distancing, remote working, and the closure of commercial activities that resulted in operational challenges. The oral biologics and biosimilar drugs market is expected to reach $10.41 billion in 2026 at a CAGR of 20.7%.

The rising prevalence of chronic diseases such as arthritis, asthma, cancer is expected to be a major driver of the oral biologics and biosimilar market.

Request A Sample For The Global Oral Biologics & Biosimilar Drugs Market Report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=3792&type=smp

The oral biologics and biosimilar market consist of sales of oral biologics and biosimilar products and related services used to treat chronic diseases such as diabetes, arthritis, cancer. Biologics are drugs made from living cells using highly complex technology while biosimilars are created to function similarly to biologics but are not identical to biologics. Biosimilars offer active properties as any licensed biologic drug. The oral biologics and biosimilar market comprise of biologics and biosimilar drugs taken orally for the targeted treatment of Alzheimer’s, multiple sclerosis, HIV/AIDS and other serious conditions.

Global Oral Biologics & Biosimilar Drugs Market Segments Include:

By Therapy: Lymphocyte Modulators, Interleukin Inhibitors, Tumor Necrosis Factor-Alpha Inhibitors

By Disease: Asthma, Crohn’s Disease, Carcinoma, Arthritis, Diabetes, Multiple Myeloma, Enterocolitis, Multiple Sclerosis, Sarcoma, Psoriasis and Others

 By Molecule Type: Vaccines, Proteins & Peptides, Monoclonal Antibodies, Others

By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

By Geography: The market is segmented into North America, South America, Asia-Pacific, Eastern Europe, Western Europe, Middle East and Africa. Among these regions, North America was the largest region in the oral biologics and biosimilar drugs market in 2021.

The latest trend in the oral biologics and biosimilar market is the creation of new insulin biosimilars. The key players operating in the oral biologics and biosimilar market are investing in creating a biosimilar copy of insulin. This is also promoting competition among various biosimilar manufacturers.

TBRC’s oral biologics & biosimilar drugs market report covers:

Major Market Players: Novartis, Rani Therapeutics, Eli Lilly and Co., AstraZeneca plc, Novo Nordisk A/S, Biocon Limited, Oramed Pharmaceuticals, BiosanaPharma, Entera Bio Ltd., Allergan plc, Emisphere Technologies, Enteris BioPharma, Chiasma, Allena Pharmaceuticals, Gelgen, Ganlee, 3sbio, Innovent, Retractable Technologies, Inc., Changchun High Tech, Dong Bao, CP Guojian, GlaxoSmithKline Plc., Concord Biotech, Aurobindo Pharma Ltd., H. Lundbeck A/S, Sanofi-Aventis and Roche.

Regions: Asia-Pacific, China, Western Europe, Eastern Europe, North America, USA, South America, Middle East and Africa.

Countries: Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA.

Time Series: Five years historic (2016-21) and ten years forecast (2022-2026-2031)

The Oral Biologics & Biosimilar Drugs Global Market Report 2022–Market Size, Trends, And Global Forecast 2022-2026 is one of a series of new reports from The Business Research Company that provides oral biologics & biosimilar drugs market overviews, analyses and forecasts market size, share, oral biologics & biosimilar drugs market players, oral biologics & biosimilar drugs market segments and geographies, leading competitor revenues, profiles and market shares.

TBRC’s oral biologics & biosimilar drugs market report identifies top countries and segments for opportunities and strategies based on market trends and leading competitors’ approaches.

Here Is A List Of Similar Reports From The Business Research Company:

Biologics Global Market Report 2022

Cancer Biologics Global Market Report 2022

Pharmaceuticals Global Market Report 2022

Interested To Know More About The Business Research Company?
The Business Research Company has published over 1000 industry reports, covering over 2500 market segments and 60 geographies. The reports draw on 150,000 datasets, extensive secondary research, and exclusive insights from interviews with industry leaders. The reports are updated with a detailed analysis of the impact of COVID-19 on various markets.

Read more about us at https://www.thebusinessresearchcompany.com/about-the-business-research-company.aspx

Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 8897263534
Americas: +1 315 623 0293
Email: info@tbrc.info
Follow us on LinkedIn: https://in.linkedin.com/company/the-business-research-company
Follow us on Twitter: https://twitter.com/tbrc_info
Check out our Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Found this article helpful? Share it on: